Our expert analysts focus in on the latest advancements, key trends and takeaways from the Orthopedic Trauma Association (OTA) meeting in Tampa, Florida held October 12–15, 2022. Major trauma manufacturers showcased innovation through new product introductions.

Despite mixed results from Trauma players, the segment experienced healthy growth as mergers and acquisitions were plentiful and regulatory clearances show promise of future new product introductions.

New products and signs of procedural recovery lighten the mood at AAOS 2022

The mood at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting was upbeat despite scaled-back attendance and exhibit space. Surgeons and exhibitors alike were excited to get back to in-person discussions about issues in orthopedics, new products hitting the market and the potential for recovery from the impact of COVID. While at the meeting, SmartTRAK met with industry professionals from clinicians to company representatives identifying key takeaways from market drivers and limiters to new product introductions.

(Continue reading to find out how to receive FREE SmartTRAK DAILY UPDATES)

New product introductions offset slightly weaker Q4 results due to COVID-19 headwinds and international pressure.

While the Trauma segment was not impacted as heavily due to COVID-19 headwinds, companies that play within the space were impacted by deferrals of elective surgeries such as limb restoration. Long bone trauma volumes remained healthy as players cited new product introductions as growth drivers for the segment. 

Among the many topics covered in detail in our comprehensive Q421/FY21 Trauma Market Recap* are:

Trauma market continues to ride the wave of healthy growth with positive returns for current players and new players start to stir the waters

Trauma players rode the wave of another quarter of healthy returns as trauma procedures were not as impacted by the rise in the Delta variant as its elective procedure counterparts. The Trauma Market closed Q3 up +4.5% YoY compared to Q320, with the US up +5.8% YoY.

Among the many topics covered in detail in our comprehensive Q321 Trauma Market Recap* are:

Trauma market rebounds as top segments drive growth amid easy YoY comps

The Trauma Market experienced another quarter of healthy growth as the WW and US Trauma Markets ended Q221 up YoY compared to Q220.  Looking forward to Q321, SmartTRAK feels that trauma procedures will likely not be as heavily impacted by the rise in the Delta variant as its elective procedure counterparts. We will continue to monitor the situation as the variant impacts states, as recently observed in Texas.

Among the many topics covered in detail in our comprehensive Q221 Trauma Market Recap* are:

After another difficult year, it's time to get out there and start reconnecting in person. SmartTRAK is excited to be traveling to Charlotte, NC to attend AOFAS at the Charlotte Convention Center, September 21-25.

SmartTRAK will be represented by Natasha Weeks, General Manager, Trauma & Extremities. Natasha is also managing our 3 newest modules, Pediatric Trauma, Pediatric Extremities and Pediatric Spine. If you would like to meet with Natasha while attending the meeting, just click here.

Now that we're back to in-person meetings, it's time to resume our continuing series Know Before You Go, so I sat down and asked Natasha a few questions about what she is looking forward to at AOFAS.

SmartTRAK outlines consequences COVID-19 is expected to have on the European Trauma & Extremities Market

Twenty-five years of orthopedic business planning has taught me to monitor certain non-business factors when setting goals. Trends in weather patterns, age demographics, lifestyle and activities can have a direct influence on market growth. In 2020, the COVID-19 pandemic negatively impacted the European market with the shutdown of various countries and the ensuing changes in lifestyle such as reduced travel, work and sporting activities. In 2020, SmartTRAK predicted the European Trauma market fell by around 25% with extremities at nearly -50% in the midst of COVID-19 lockdowns. Similar market pressures are also expected during 2021.

Healthy growth closes out Q420 as the trauma segment recovers in the second half of the year hitting pre-COVID levels.

Despite the rise in COVID cases during Q4, the Trauma Market fared well resulting in positive YoY revenue gains that represented healthy, pre-COVID level volumes. Trauma players cited another quarter of healthy trauma growth, as the second half of the year ended on an upswing (+5.6% vs. H219). Top US market leaders, DePuy Synthes (49.4% Q420 US share), Stryker (27.3%) and Smith & Nephew (9.8%) all reported improved sequential gains.

Among the many topics covered in the comprehensive Q420/FY20 Trauma Market Recap* are: